Peer-influenced content. Sources you trust. No registration required. This is HCN.

MDLinxExperimental drug breaks record for weight loss in latest clinical trial results

Lilly Pharmaceutical’s Mounjaro (tirzepatide) is a once-weekly injection that promotes weight loss by mimicking the effects of incretins. This combination of a GLP-1 and a glucose-dependent insulinotropic polypeptide (GIP) yields weigh loss results comparable to surgical options.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form